Mechanisms responsible for pulmonary hypertension

Chinese Medical Journal

Volumn 121, Issue 24, 2008, Pages 2604-2609

  Prabha, Mainali ^a   Jin, Hong Fang ^a   Tian, Yue ^a   Tang, Chao Shu ^a,b   Du, Jun Bao ^a,b  

^a PEKING UNIVERSITY FIRST HOSPITAL   (China)

^b BEIJING UNIVERSITY OF POSTS AND TELECOMMUNICATIONS   (China)

Author keywords

Endothelial cells; Extracellular matrix; Hydrogen sulfide; Hypertension, pulmonary; Myocytes, smooth muscle

Indexed keywords

ADRENOMEDULLIN; ANTINUCLEAR ANTIBODY; ARGININE; BONE MORPHOGENETIC PROTEIN RECEPTOR 1A; BONE MORPHOGENETIC PROTEIN RECEPTOR 2; BOSENTAN; CARBON MONOXIDE; CASPASE 3; DEXFENFLURAMINE; ELASTIN; ENDOTHELIN 1; GLYCERYL TRINITRATE; HEME OXYGENASE; HYDROGEN SULFIDE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; IMMUNOSUPPRESSIVE AGENT; INTERLEUKIN 1; INTERLEUKIN 6; INTERSTITIAL COLLAGENASE; MESSENGER RNA; NITRIC OXIDE; NITRIC OXIDE DONOR; NITRIC OXIDE SYNTHASE; POTASSIUM CHANNEL; PROCOLLAGEN; PROSTACYCLIN; PROTEIN BCL 2; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TRANSFORMING GROWTH FACTOR BETA RECEPTOR 2; UNINDEXED DRUG;

ANTIHYPERTENSIVE ACTIVITY; APOPTOSIS; ARTERY MUSCLE; ARTICLE; CELL PROLIFERATION; DRUG EFFICACY; DRUG TARGETING; ENDOTHELIUM CELL; EXTRACELLULAR MATRIX; FIBRINOLYSIS; GENE MUTATION; HEREDITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOSUPPRESSIVE TREATMENT; INCIDENCE; INFLAMMATORY CELL; LUNG FIBROBLAST; NONHUMAN; PATHOPHYSIOLOGY; PROTEIN EXPRESSION; PULMONARY ARTERY OCCLUSION; PULMONARY HYPERTENSION; SMOOTH MUSCLE FIBER; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGLUTINATION;

EID: 60649119653     PISSN: 03666999     EISSN: None     Source Type: Journal    
DOI: 10.1097/00029330-200812020-00024     Document Type: Article

References (45)

1. Wang XX, Zhang FR, Shang YP, Zhu JH, Xie XD, Tao QM, et al. Transplantation of autologous endothelial progenitor cells may be beneficial in patients with idiopathic pulmonary arterial hypertension: a pilot randomized controlled trial. J Am Coll Cardiol 2007; 49: 1566-1571.
2. Zaiman A, Fijalkowska I, Hassoun PM, Tuder RM. One hundred years of research in the pathogenesis of pulmonary hypertension. Am J Respir Cell Mol Biol 2005; 33: 425-431.
3. Stenmark KR, McMurty IF. Vascular remodeling vesus vasoconstriction in chronic hypoxic pulmonary hypertension: a time for reappraisal? Circ Res 2005; 97: 95-98:
4. Mandegar M, Fung YC, Huang W, Remillard CV, Rubin LJ, Yuan JX. Cellular and molecular mechanisms of pulmonary vascular remodeling: role in the development of pulmonary hypertension. Microvas Res 2004; 68: 75-103.
5. Qi JG, Tang XY, Du JB, Zhang Y, Chai LJ, Tang CS. Influence of high pulmonary blood flow on ultrastructure of intra-acinar pulmonary arteries in rats. J Chin Electr Micros Soc (Chin) 2002; 21: 380-382.
6. Lee SD, Shroyer KR, Markhaam NE, Cool CD, Voelkel NF, Tuder RM. Monoclonal endothelial cell proliferation in present in primary but not secondary pulmonary hypertension. J Clin Invest 1998; 101: 927-934.
7. Yeager ME, Halley GR, Golpon HA, Voelkel NF, Tuder RM. Microsatellite instability of endothelial cell growth and apoptosis genes with plexiform lesions in primary pulmonary hypertension. Circ Res 2001; 88: E8-E11.
8. Tang XY,, Du JB, Qi, JG, Shi Y, Shi L, Zhang Y, et al. Ultrastructural observation of intra-acinar pulmonary arteries on experimental hypoxic pulmonary hypertension. J Chin Electr Micros Soc (Chin) 2004; 23: 522-525.
9. Wei B, Du JB, Li J, Zhang CY, Qi JG, Tang CS. Effect of high pulmonary blood flow on pulmonary artery pressure and pulmonary artery smooth muscles cell proliferation and apoptosis J Peking Univ (Health Sci) (Chin) 2002, 34:43-47.
10. Li FH, Xia W, Li AW, Zhao CF, Sun RP. Inhibition of rho kinase attennuates high flow induced pulmonary hypertension in rats. Chin Med J 2007, 120: 22-29.
11. Du JB, Yan H, Wei B, Qi JG, Li J, Tang CS. Effect of L-arginine on collagen of high flow induced pulmonary arterial remodeling. Circ J 2005; 69: 603-608.
12. Shi Y, Du JB, Tang XY, Tang CS. Pulmonary vascular microstructure in chronic hypoxic pulmonary hypertension. J Appl Clin Pediatr (Chin) 2002; 17:1-4.
13. Cheever KH. An overview of pulmonary arterial hypertension. J Cardiovas Nurs 2005; 20: 108-116.
14. Newman JH, Fanburg BL, Archer SL,Badesch DB, Barst RJ, Garcia JG, et al. Pulmonary arterial hypertension future directions: Report of a national heart, lung and blood institute/office of rare diseases workshop. Circulation 2004; 109: 2947-2952.
15. Qi J, Du J, Tang X, Li J, Wei B, Tang C. The upregulation of endothelial nitric oxide synthase and urotensin-II is associated with pulmonary hypertension and vascular diseases in rats produced by aortocaval shunting. Heart Vessels 2004; 19: 81-88.
16. Qi JG, Du JB, Jia JF. Endogenous nitric oxide regulates hypoxic pulmonary vascular remodeling in rats. Chin J Pediatr (Chin) 1999; 37: 104-106.
17. Qi JG, Du JB, Wang L, Zhao B, Tang CS. Alleviation of hypoxic pulmonary vascular structural remodeling by L-arginine. Chin Med J 2001; 114: 933-936.
18. Shi Y, Du JB, Zeng CM, Tang CS. Role of endogenous carbon monoxide/heme oxygenase (CO/HO) system in the development of hypoxic pulmonary hypertension. Chin J Pediatr (Chin) 2002; 40: 47-51.
19. Shi Y, Du JB, Gong LM, Zeng CM, Tang XY, Tang CS. The regulating effect of heme oxygenase/carbon monoxide on hypoxic pulmonary vascular structural remodeling. Biochem Biophys Res Commun 2003; 306: 523-529.
20. Du JB, Chen XB, Geng B, Jiang HF, Tang CS. Hydrogen sulfide as a messenger molecule in cardiovascular system. J Peking Univ (Health Sci) (Chin) 2002; 34: 187.
21. Zhang CY, Du JB, Bu DF, Yan H, Tang XY, Tang CS. The regulatory effect of hydrogen sulfide on hypoxic pulmonary hypertension in rats. Biochem Biophys Res Commun 2003; 302: 810-816.
22. Zhaag CY, Du JB, Bu DF, yan H, Tang XY, Si Q, et al. The regulatory effect of endogenous hydrogen sulfide on hypoxic pulmonary hypertension. J Peking Univ (Health Sci) (Chin) 2003; 35: 488-493.
23. Zhang QY, Du JB, Zhao WJ, Yan H, Tang CS, Zhang CY. Impact of hydrogen sulfide on carbon monoxide/heme oxygenase pathyway in the pathogenesis of hypoxic pulmonary hypertension. Biochem Biophys Res Commun 2004; 317: 30-37.
24. Wang YF, Mainali P, Tang CS, Shi L, Zhang CY, Yan H, et al. Effects of nitric oxide and hydrogen sulfide on the relaxation of pulmonary arteries inn rats. Chin Med J 2008; 121: 420-423.
25. Jia HF, DU SX, Zhao X, Zhang SQ, Tian Y, Bu DF, et al. Significance of endogenous sulfur dioxide in the regulation of cardiovascular system. J Peking Univ (Health Sci) (Chin) 2007; 39: 423-425.
26. Du SX, Du JB, Tang CS. Advances in study of physiologic effects of endogenous sulfur dioxide and its derivatives. J Peking Univ (Health Sci) (Chin) 2006; 38: 331-334.
27. Du SX, Zhang CY, Jin HF, Du JB, Tang CS. Vasorelaxant effect of sulfur dioxide derivatives on isolated aortic rings of rats and its Mechanisms. J Peking Univ (Health Sci) (Chin) 2006; 38: 581-585.
28. Tuder RM, Cool CD, Geraci MW, Wang J, Abman SH, Wright L, et al. Prostacyclin synthase expression is decreased in lungs from patients with severe pulmonary hypertension. Am J Respir Crit Care Med 1999; 159: 1925-1932.
29. Barst RJ, Rubin LJ, Long WA, McGoon MD, Rich S, Badesch DB, et al. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. The Primary Pulmonary Hypertension Study Group. N Engl J Med 1996; 334: 296-302.
30. Qi JG, Ding YG, Tang CS, Du JB. Chronic administration of adrenomedullin attenuates hypoxic pulmonary vascular structural remodeling and inhibits proadrenomedullin N-terminal 20-peptide production in rats. Peptides 2007; 28: 910-919.
31. Yoshihara F, Nishikimi T, Horio T, Yutani C, Takishita S, Matsuo H, et al. Chronic infusion of adrenomedullin reduces pulmonary hypertension and lessens right ventricular hypertrophy in rats administered monocrotaline. Eu J Pharmocol 1998; 355: 33-39.
32. Nagaya N, Kyotani S, Uematsu M, Ueno K, Oya H, Nakanishi N, et al. Effects of adrenomedullin inhalation on hemodynamics and exercise capacity in patients with idiopathic pulmonary arterial hypertension. Circulation 2004; 109: 351-356.
33. Du JB, Li WZ, Li W, Zhao B. Endothelin mRNA expression and its localization in intrapulmonary arteries of chronic hypoxic rats, J Peking Univ (Chin)1997; 29: 15-17.
34. Rubin LJ, Badesch DB, Barst RJ, Galie N, Black CM, Keogh A, et al. Bosentan therapy for pulmonary arterial hypertension. N Engl J Med 2002; 346: 896-903.
35. Nong Z, Stassen JM, Moons L, Collen D, Janssens S. Inhibition of tissue angiotensin-converting enzyme with quinapril reduces, hypoxic pulmonary hypertension and pulmonary vascular remodeling. Circulation 1996; 94: 1941-1947
36. Eddahibi S, Hanoun N, Lanfumey L, Lesch KP, Raffestin B, Hamon M, et al. Attenuated hypoxic pulmonary hypertension in mice lacking the 5-hydroxytryptamine transporter gene. J Clin Invest 2000; 105: 1555-1562.
37. Eddahibi S, Humbert M, Fadel E, Raffestin B, Darmon M, Capron F, et al. Serotonin transporter overexpression is responsible for pulmonary arery smooth muscle cell hyperplasia in primary pulmonary hypertension. J Clin Invest 2001; 108: 1141-1150.
38. + channels in pulmonary artery smooth muscle cells of patients with primary pulmonary hypertension. Circulation 1998; 98: 1400-1406.
39. Abenhaim L, Moride Y, Brenot F, Rich S, Benichou J, Kurz X, et al. Appetite-suppressant drugs and the risk of primary pulmonary hypertension. International Primary Pulmonary Hypertension Study Group. N Engl J Med 1996; 335: 609-616.
40. Dresdale DT, Michtom RJ, Shultz M. Recent studies in primary pulmonary hypertension, including pharmacodynamic observations on pulmonary vascular disease. Bull N Y Acad Med 1954; 30: 195-207.
41. Morse JH, Jones AC, Barst RJ, Hodge SE, Wilhelmsen KC, Nygaard TG Mapping of familial primary pulmonary hypertensive locus (PPH1) to chromosome 2q31-q32. Circulation 1997; 95: 2603-2606.
42. Deng Z, Morse JH, Slager SL, Cuervo N, Moore KJ, Venetos G, et al. Familial primary pulmonary hypertension (gene PPH1) is caused by mutations in the bone morphogenetic protein receptor - II gene. Am J Hum Genet 2000; 67: 737-744.
43. Lane KB, Machado RD, Pauciulo MW, Thomson JR, Phillips JA 3rd, Loyd JE, et al. Heterozygous germline mutations in BMPR2, encoding a TGF-beta receptor, cause familial primary pulmonary hypertension. The International PPH Consortium. Nat Genet 2000; 26: 3-4.
44. Sztrymf B, Yaïci A, Girerd B, Humbert M. Genes and pulmonary arterial hypertension. Respiration 2007; 74: 123432.
45. Foletta VC, Lim MA, Soosairajah J, Kelly AP, Stanley EG. Direct signaling by the BMP type II receptor via the cytoskeletal regulator LIMK1. J Cell Biol 2003; 163: 421.